Incyte Corporation
INCY
Rang in Aktien
#1001
Incyte Corporation is a biopharmaceutical firm engaged in the research,... Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
Aktienkurs
$116.04
Marktkapitalisierung
$23.52B
Veränderung (1 Tag)
2.46%
Veränderung (1 Jahr)
34.66%
Land
US
Handel Incyte Corporation (INCY)
Kategorie
Healthcare
Gewinn für Incyte Corporation (INCY)
Gewinn im Jun 2026 TTM: $1.97B
Laut den aktuellen Finanzberichten von Incyte Corporation betragen die aktuellen Gewinne des Unternehmens $1.97B. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $316.63M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2023, der $834.22M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Incyte Corporation von 2000 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $1.97B | 18.20% |
| 2025 | $1.66B | 425.68% |
| 2024 | $316.63M | -62.04% |
| 2023 | $834.22M | 57.66% |
| 2022 | $529.12M | -7.24% |
| 2021 | $570.44M | -345.65% |
| 2020 | $-232.22M | -147.70% |
| 2019 | $486.79M | 322.02% |
| 2018 | $115.35M | -136.94% |
| 2017 | $-312.29M | -390.76% |
| 2016 | $107.40M | 1,321.44% |
| 2015 | $7.56M | -115.56% |
| 2014 | $-48.55M | -41.40% |
| 2013 | $-82.85M | 87.67% |
| 2012 | $-44.15M | -76.33% |
| 2011 | $-186.54M | 485.76% |
| 2010 | $-31.85M | -84.97% |
| 2009 | $-211.87M | 18.42% |
| 2008 | $-178.92M | 105.94% |
| 2007 | $-86.88M | 17.14% |
| 2006 | $-74.17M | -28.62% |
| 2005 | $-103.91M | -36.33% |
| 2004 | $-163.21M | -1.67% |
| 2003 | $-165.99M | 22.26% |
| 2002 | $-135.77M | -27.39% |
| 2001 | $-186.97M | 472.35% |
| 2000 | $-32.67M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $5.27B | 168.12% |
US
|
|
| $-3.09B | -256.91% |
US
|
|
| $-4.02B | -304.14% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -0.85% |
NL
|
